- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Aeolus Pharmaceuticals announced the presentation of new data on AEOL 10150 for the treatment of the pulmonary effects of acute radiation syndrome.
Aeolus Pharmaceuticals (OTCQB:AOLS) announced the presentation of new data on AEOL 10150 for the treatment of the pulmonary effects of acute radiation syndrome.
As quoted in the press release:
The analysis, performed by Jogarao Gobburu, PhD, Vijay Ivaturi, PhD and Hechuan Wang, MS with the Center for Translational Medicine at the University of Maryland School of Pharmacy and funded by Aeolus’ Lung ARS development contract with the Biomedical Advanced Research and Development Authority (“BARDA”) confirmed the statistical significance of the improvement in survival and underlying pathophysiology seen after treatment with AEOL 10150 in NHP efficacy studies conducted by and previously reported by Thomas MacVittie, PhD at the University of Maryland School of Medicine (“UMSOM”).
Dr. Gobburu’s analysis of data from NHP and mouse efficacy studies, performed under the BARDA contract, concluded that administration of AEOL 10150 for 60 days beginning 24 hours after exposure to lethal radiation provided the best survival benefit and that this level of efficacy demonstrated in an “adequate and well designed” study would likely produce a dose modification factor supporting approval under the Animal Rule.
Click here to read the full press release.
Source: www.accesswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.